Fort Myers Newswire

Fort Myers Newswire

Comprehensive Real-Time News Feed for Fort Myers, FL.

Results 1 - 20 of 22 for "u:americanbankingnews.com" in Fort Myers, FL

  1. Recent Research Analysts' Ratings Changes for NeoGenomicsRead the original story w/Photo

    Friday Jul 15 | AmericanBankingNews.com

    They now have a $10.00 price target on the stock. 7/7/2016 - NeoGenomics was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating.

    Comment?

  2. NeoGenomics Inc. (NEO) Upgraded by Zacks Investment Research to BuyRead the original story w/Photo

    Saturday Jul 9 | AmericanBankingNews.com

    The firm presently has a $9.25 price objective on the stock. Zacks Investment Research's target price would suggest a potential upside of 1.09% from the company's previous close.

    Comment?

  3. NeoGenomics Inc. (NEO) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Thursday Jul 7 | AmericanBankingNews.com

    The brokerage currently has a $9.25 target price on the stock. Zacks Investment Research's price objective indicates a potential upside of 13.22% from the stock's current price.

    Comment?

  4. NeoGenomics Inc. (NEO) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Sunday Jul 3 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  5. Zacks Investment Research Lowers NeoGenomics, Inc. (NEO) to HoldRead the original story w/Photo

    Wednesday Jun 29 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  6. NeoGenomics, Inc. (NEO) Upgraded to "Strong-Buy" by Zacks Investment ResearchRead the original story w/Photo

    May 25, 2016 | AmericanBankingNews.com

    They currently have $9.75 price objective on the stock. According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.

    Comment?

  7. NeoGenomics, Inc. (NEO) Rating Increased to Strong-Buy at Zacks Investment ResearchRead the original story w/Photo

    May 20, 2016 | AmericanBankingNews.com

    The brokerage presently has a $9.75 price target on the stock. Zacks Investment Research 's price objective would suggest a potential upside of 13.37% from the company's current price.

    Comment?

  8. NeoGenomics, Inc. (NEO) Upgraded to "Strong-Buy" at Zacks Investment ResearchRead the original story w/Photo

    May 20, 2016 | AmericanBankingNews.com

    The firm presently has a $9.75 price target on the stock. Zacks Investment Research 's target price would indicate a potential upside of 13.37% from the stock's current price.

    Comment?

  9. NeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to Strong-BuyRead the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    The brokerage currently has a $9.75 target price on the stock. Zacks Investment Research 's price target suggests a potential upside of 15.11% from the stock's previous close.

    Comment?

  10. NeoGenomics, Inc. (NEO) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  11. NeoGenomics (NEO) - Analysts' Recent Ratings ChangesRead the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  12. NeoGenomics, Inc. (NEO) Upgraded to "Buy" at Zacks Investment ResearchRead the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    The brokerage currently has $7.50 price target on the stock. According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.

    Comment?

  13. Weekly Investment Analysts' Ratings Updates for NeoGenomicsRead the original story w/Photo

    Mar 21, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  14. NeoGenomics, Inc. (NEO) Lifted to Buy at Zacks Investment ResearchRead the original story w/Photo

    Mar 19, 2016 | AmericanBankingNews.com

    The brokerage currently has a $7.50 target price on the stock. Zacks Investment Research 's price target suggests a potential upside of 19.62% from the stock's current price.

    Comment?

  15. NeoGenomics, Inc. (NEO) Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Mar 19, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  16. Zacks Investment Research Lowers NeoGenomics, Inc. (NEO) to HoldRead the original story w/Photo

    Mar 19, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  17. NeoGenomics, Inc. (NEO) Raised to "Buy" at Zacks Investment ResearchRead the original story w/Photo

    Mar 16, 2016 | AmericanBankingNews.com

    The brokerage currently has a $7.50 target price on the stock. Zacks Investment Research 's price target points to a potential upside of 12.44% from the company's previous close.

    Comment?

  18. Zacks Investment Research Lowers NeoGenomics, Inc. (NEO) to SellRead the original story w/Photo

    Feb 24, 2016 | AmericanBankingNews.com

    According to Zacks, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.

    Comment?

  19. Weekly Analysts' Ratings Updates for NeoGenomicsRead the original story

    Nov 16, 2015 | AmericanBankingNews.com

    They now have a "buy" rating on the stock. 11/2/2015 - NeoGenomics was downgraded by analysts at Zacks from a "hold" rating to a "sell" rating.

    Comment?

  20. Research Analysts' Recent Ratings Updates for NeoGenomicsRead the original story

    Nov 5, 2015 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of NeoGenomics in the last few weeks: 11/2/2015 - NeoGenomics had its price target raised by analysts at Craig Hallum from $8.00 to $10.00. They now have a "buy" rating on the stock.

    Comment?

Fort Myers Job Listings
View or post Fort Myers job listings on Topix.
Fort Myers Real Estate
News, listings, and foreclosures in Fort Myers from Topix.
Fort Myers Mortgages
Find mortgage rates in Fort Myers on Topix.